Medpace Holdings (MEDP) EBITDA (2015 - 2026)

Medpace Holdings (MEDP) has reported EBITDA for 12 consecutive years, with $153.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 15.23% year-over-year to $153.4 million; the trailing twelve-month figure through Jun 2026 stood at $610.4 million (up 20.81% YoY), and the FY2025 full-year result was $562.1 million, up 18.42% from the prior year.
• EBITDA grew to $153.4 million in Q2 2026 per MEDP's latest filing, from $148.3 million in the prior quarter.
• Across five years, EBITDA topped out at $160.2 million in Q4 2025 and bottomed at $64.9 million in Q2 2022.
• Historically, EBITDA has averaged $110.9 million across 5 years, with a median of $111.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: EBITDA jumped 43.29% in 2022, then gained 8.6% in 2025.
• Over 5 years, EBITDA stood at $81.5 million in 2022, then gained by 15.02% to $93.7 million in 2023, then soared by 41.37% to $132.5 million in 2024, then rose by 20.87% to $160.2 million in 2025, then slipped by 4.25% to $153.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $153.4 million, $148.3 million, and $160.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.